Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 135.50
+1.00 (0.74%)
Aug 14, 2025, 1:30 PM CST
TPE:6919 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 7,573 | 6,901 | 3,422 | 655.05 | 594.91 | 93.56 | Upgrade
|
| Short-Term Investments | 1,826 | 2,767 | 289.4 | 456.18 | - | - | Upgrade
|
| Cash & Short-Term Investments | 9,400 | 9,669 | 3,712 | 1,111 | 594.91 | 93.56 | Upgrade
|
| Cash Growth | 181.44% | 160.51% | 234.01% | 86.79% | 535.87% | 331.36% | Upgrade
|
| Accounts Receivable | 0.21 | 5.18 | 7.89 | 3.12 | - | - | Upgrade
|
| Receivables | 0.21 | 5.18 | 7.89 | 3.12 | - | - | Upgrade
|
| Inventory | 7.31 | 2.86 | 1.02 | 2.81 | 0.05 | 2.53 | Upgrade
|
| Other Current Assets | 36.19 | 29.12 | 23.16 | 14.87 | 10.32 | 14.96 | Upgrade
|
| Total Current Assets | 9,443 | 9,706 | 3,744 | 1,132 | 605.27 | 111.05 | Upgrade
|
| Property, Plant & Equipment | 53.67 | 61.32 | 80.41 | 99.6 | 106.38 | 114.68 | Upgrade
|
| Other Intangible Assets | - | - | - | - | - | 0.07 | Upgrade
|
| Other Long-Term Assets | 2.93 | 3.14 | 2.46 | 1.46 | 1.26 | 1.26 | Upgrade
|
| Total Assets | 9,500 | 9,771 | 3,827 | 1,233 | 712.9 | 227.05 | Upgrade
|
| Accounts Payable | 0.01 | 0.97 | 1.7 | 2.53 | 0.33 | 0.74 | Upgrade
|
| Accrued Expenses | - | 1.97 | - | - | 30.98 | 45.14 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 1.17 | 7.97 | Upgrade
|
| Current Portion of Leases | 7.46 | 8.88 | 8.58 | 8.22 | 7.03 | 6.79 | Upgrade
|
| Current Unearned Revenue | 7.7 | 3.61 | 1.03 | 4.5 | - | - | Upgrade
|
| Other Current Liabilities | 64.84 | 37.32 | 62.37 | 33.11 | 0.16 | 3.82 | Upgrade
|
| Total Current Liabilities | 80.01 | 52.74 | 73.68 | 48.36 | 39.67 | 64.45 | Upgrade
|
| Long-Term Debt | - | - | - | - | 3.55 | 83.95 | Upgrade
|
| Long-Term Leases | - | 3 | 11.87 | 20.46 | 25.02 | 32.06 | Upgrade
|
| Other Long-Term Liabilities | 23.58 | 17.71 | - | - | - | - | Upgrade
|
| Total Liabilities | 103.59 | 73.7 | 85.55 | 68.82 | 68.24 | 180.46 | Upgrade
|
| Common Stock | 775.51 | 769.14 | 696.62 | 615.55 | 535.93 | 312.17 | Upgrade
|
| Additional Paid-In Capital | 9,250 | 9,131 | 3,271 | 834.46 | 217.47 | 106.85 | Upgrade
|
| Retained Earnings | -248.81 | -56.14 | -227.31 | -286.16 | -107.41 | -371.05 | Upgrade
|
| Treasury Stock | - | - | -0.07 | -0.08 | -0.09 | - | Upgrade
|
| Comprehensive Income & Other | -380.06 | -147.47 | 0.81 | 0.49 | -1.24 | -1.38 | Upgrade
|
| Shareholders' Equity | 9,396 | 9,697 | 3,741 | 1,164 | 644.66 | 46.6 | Upgrade
|
| Total Liabilities & Equity | 9,500 | 9,771 | 3,827 | 1,233 | 712.9 | 227.05 | Upgrade
|
| Total Debt | 7.46 | 11.87 | 20.46 | 28.68 | 36.78 | 130.76 | Upgrade
|
| Net Cash (Debt) | 9,392 | 9,657 | 3,691 | 1,083 | 558.13 | -37.2 | Upgrade
|
| Net Cash Growth | 182.59% | 161.63% | 240.96% | 93.96% | - | - | Upgrade
|
| Net Cash Per Share | 6.34 | 6.75 | 2.98 | 0.92 | 0.61 | -0.05 | Upgrade
|
| Filing Date Shares Outstanding | 1,555 | 1,538 | 1,393 | 1,231 | 1,072 | 832.92 | Upgrade
|
| Total Common Shares Outstanding | 1,555 | 1,538 | 1,393 | 1,231 | 1,072 | 832.92 | Upgrade
|
| Working Capital | 9,363 | 9,653 | 3,670 | 1,084 | 565.6 | 46.6 | Upgrade
|
| Book Value Per Share | 6.04 | 6.30 | 2.69 | 0.95 | 0.60 | 0.06 | Upgrade
|
| Tangible Book Value | 9,396 | 9,697 | 3,741 | 1,164 | 644.66 | 46.53 | Upgrade
|
| Tangible Book Value Per Share | 6.04 | 6.30 | 2.69 | 0.95 | 0.60 | 0.06 | Upgrade
|
| Machinery | - | 138.75 | 129.99 | 121.55 | 112.76 | 76.42 | Upgrade
|
| Construction In Progress | - | - | 1.14 | 1.82 | 0.3 | 31.29 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.